Charles River Laboratories Intl (CRL) Stock Price, Quote & News

Company Profile

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. The Research Models and Services segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, includi...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 781 222 6000

Website: www.criver.com

Address:

251 Ballardvale Street, Wilmington, United States

YouOnlyLiveTwice May. 13 at 2:02 PM

$CRL $TMO These o my one that has growth in excess of 7% is RVTY and the only one w cloud based AI technology

0 · Reply

YouOnlyLiveTwice May. 13 at 1:59 PM

$CRL $TMO These are dead stocks .. They have NO growth ….

1 · Reply

CapitalMonk May. 13 at 3:39 AM

$CRL Price: $168.69 (+0.14%) Trend: Bearish Market Bias (7D): Sideways ⚖️ Expected Range: ±1.23% RSI: 38.3 | Momentum: Strong Downside Volume: -39.8% vs avg Volatility: 3.50% Support: $161.95 | Resistance: $194.57 Tools used: https://www.trade-ideas.com Code: INTERSTOCK25

0 · Reply

YouOnlyLiveTwice May. 12 at 7:51 PM

$RVTY $BSX $CRL $TMO

0 · Reply

YouOnlyLiveTwice May. 11 at 3:50 PM

$CRL Nobody wants company w 1% growth when you have tech and industrials growing in double digits

0 · Reply

MarketBeat May. 9 at 11:04 PM

https://marketbeat.com/a/8644554/ $CRL Charles River Laboratories International Q1 Earnings Call Highlights

0 · Reply

StocktwitsEarnings May. 7 at 11:22 AM

$CRL Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.30 down -160.00% YoY • Reported revenue of $995.83M up 1.18% YoY • Charles River reaffirms its 2026 organic revenue guidance of (1.5)% to (0.5)% and non-GAAP EPS guidance of $10.80 to $11.30, but reduced its reported revenue outlook by approximately 50 basis points.

0 · Reply

SuperGreenToday Apr. 28 at 6:49 PM

$CRL Share Price: $165.87 Contract Selected: Aug 21, 2026 $170 Calls Buy Zone: $21.34 – $26.36 Target Zone: $35.30 – $43.14 Potential Upside: 56% ROI Time to Expiration: 114 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

YouOnlyLiveTwice Apr. 23 at 4:19 PM

$CRL All med device are sells …

0 · Reply

zerodayrounder Apr. 23 at 1:58 PM

$CRL this thing is cooked wow. AI eating its lunch?

0 · Reply

Charles River Laboratories and MEDIPOST Sign Non-Exclusive MOU to Advance GMP Testing Solutions

2026-05-11T15:58:54.000Z - 1 day ago

Charles River announces ‘continued momentum’ in digital pathology platform

May 11, 2026, 8:00 AM EDT - 2 days ago

Charles River Accelerates Digital Pathology with AI-Powered End-to-End Workflow

2026-05-08T18:35:02.000Z - 4 days ago

Charles River price target raised to $220 from $200 at Evercore ISI

2026-05-08T16:50:05.000Z - 4 days ago

Charles River price target raised to $213 from $200 at Baird

2026-05-08T13:29:48.000Z - 5 days ago

Charles River price target raised to $192 from $175 at Mizuho

2026-05-08T10:20:10.000Z - 5 days ago

Charles River price target raised to $220 from $210 at Barclays

May 7, 2026, 8:30 AM EDT - 6 days ago

Charles River Laboratories International Earnings Call Transcript: Q1 2026

May 7, 2026, 8:05 AM EDT - 6 days ago

Charles River Associates (CRA) Reports Financial Results for the First Quarter of 2026

May 7, 2026, 8:00 AM EDT - 6 days ago

Charles River Associates (CRA) Declares Quarterly Cash Dividend of $0.57 Per Common Share

May 7, 2026, 7:54 AM EDT - 6 days ago

Charles River beats quarterly estimates on steady demand for drug development services

May 7, 2026, 7:00 AM EDT - 6 days ago

Charles River Laboratories Announces First-Quarter 2026 Results

2026-04-30T16:52:05.000Z - 12 days ago

Charles River launches rat in vitro fertility services

Apr 30, 2026, 8:00 AM EDT - 13 days ago

Charles River Launches Rat In Vitro Fertility Services Demonstrating Embryology Capabilities

Apr 23, 2026, 8:30 AM EDT - 20 days ago

Charles River Associates (CRA) to Host First-Quarter Fiscal 2026 Financial Results Conference Call on May 7

2026-04-21T13:34:36.000Z - 22 days ago

Charles River reports results of restrospective analysis on VCGs in toxicology

Apr 21, 2026, 8:00 AM EDT - 22 days ago

Charles River Highlights Effectiveness of VCGs in Toxicology

Apr 16, 2026, 8:00 AM EDT - 27 days ago

Charles River Laboratories Schedules First-Quarter 2026 Earnings Release and Conference Call

2026-04-14T10:49:28.000Z - 4 weeks ago

Charles River price target raised to $210 from $200 at Barclays

2026-04-14T00:20:43.000Z - 4 weeks ago

Charles River initiated with an Outperform at RBC Capital

Apr 13, 2026, 11:41 AM EDT - 4 weeks ago

Earnings Season Is Here. Microsoft and 7 More Companies That Usually Deliver.

MSFT ADBE APH BSX INTU NVDA WDAY

2026-04-13T13:40:53.000Z - 4 weeks ago

Charles River price target lowered to $160 from $165 at JPMorgan

Apr 9, 2026, 4:30 PM EDT - 4 weeks ago

Charles River Advances Cardiovascular Health Awareness Through Support of the American Heart Association

Apr 6, 2026, 8:55 AM EDT - 5 weeks ago

NYSE Content Update: Join Us and 6,500+ Attendees at Marquee AI Event HumanX

Mar 10, 2026, 10:00 AM EDT - 2 months ago

Charles River Laboratories International Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 3, 2026, 9:50 AM EST - 2 months ago

Charles River Laboratories International Transcript: TD Cowen 46th Annual Health Care Conference

Mar 2, 2026, 8:00 AM EST - 2 months ago

Charles River Laboratories to Present at TD Cowen and Barclays Conferences

2026-02-25T13:48:46.000Z - 2 months ago

Charles River price target raised to $175 from $170 at UBS

Feb 25, 2026, 8:00 AM EST - 2 months ago

Charles River raises annual profit view as it sells underperforming assets

2026-02-25T12:36:22.000Z - 2 months ago

Iqvia to acquire certain discovery services assets from Charles River

IQV

Feb 25, 2026, 7:00 AM EST - 2 months ago

Charles River Laboratories Provides Update on Planned Divestitures

2026-02-20T14:18:16.000Z - 2 months ago

Charles River price target lowered to $235 from $251 at TD Cowen

2026-02-20T12:39:48.000Z - 2 months ago

Charles River price target lowered to $175 from $215 at Mizuho

2026-02-19T14:00:13.000Z - 2 months ago

Charles River price target lowered to $193 from $231 at Baird

2026-02-19T13:18:11.000Z - 2 months ago

Charles River price target lowered to $200 from $260 at Evercore ISI

Feb 18, 2026, 8:30 AM EST - 3 months ago

Charles River Laboratories International Earnings Call Transcript: Q4 2025

Feb 18, 2026, 7:54 AM EST - 3 months ago

Charles River forecasts upbeat 2026 profit on improved demand for drug development services

Feb 18, 2026, 7:01 AM EST - 3 months ago

Charles River Laboratories Announces Executive Appointments

Feb 18, 2026, 7:00 AM EST - 3 months ago

Charles River Laboratories Announces Fourth-Quarter and Full-Year 2025 Results and Provides 2026 Guidance

Feb 12, 2026, 11:54 AM EST - 3 months ago

Halper Sadeh LLC Encourages Charles River Laboratories International, Inc. Shareholders to Contact the Firm to Discuss Their Rights

Jan 21, 2026, 4:30 PM EST - 3 months ago

Charles River Laboratories Schedules Fourth-Quarter 2025 Earnings and 2026 Guidance Release and Conference Call

Jan 21, 2026, 8:00 AM EST - 4 months ago

Charles River Enters Manufacturing Collaboration with Gazi University

Jan 20, 2026, 3:39 PM EST - 4 months ago

Charles River Laboratories Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Charles River Laboratories International, Inc. - CRL

Jan 13, 2026, 1:30 PM EST - 4 months ago

Charles River Laboratories International Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 12, 2026, 5:19 PM EST - 4 months ago

Charles River to buy Cambodia-based monkey supplier for $510 million

Jan 12, 2026, 4:30 PM EST - 4 months ago

Charles River Laboratories Provides Business Updates

Jan 8, 2026, 8:00 AM EST - 4 months ago

Charles River Laboratories Announces Planned Retirement of James C. Foster and CEO Succession Plan

Dec 11, 2025, 8:00 AM EST - 5 months ago

Charles River Extends Commitment to Advanced Therapy Developers with Second Incubator Program Cohort

Dec 4, 2025, 8:30 AM EST - 5 months ago

T. Rowe Price Transitions to Charles River's Enterprise Multi-Asset Investment Management Platform

Dec 3, 2025, 10:00 AM EST - 5 months ago

Charles River Laboratories International Transcript: Evercore ISI 8th Annual HealthCONx Conference

Dec 1, 2025, 3:42 PM EST - 5 months ago

HALPER SADEH LLC ENCOURAGES CHARLES RIVER LABORATORIES INTERNATIONAL, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS

Dec 1, 2025, 8:00 AM EST - 5 months ago

Charles River Laboratories to Present at Evercore Healthcare Conference

Nov 18, 2025, 8:00 AM EST - 6 months ago

SOLVE and Charles River Development Partner to Deliver Integrated Fixed Income Pricing for Investment Managers

Nov 18, 2025, 6:30 AM EST - 6 months ago

Charles River Laboratories International Transcript: Jefferies London Healthcare Conference 2025

Nov 17, 2025, 8:00 AM EST - 6 months ago

Charles River Laboratories to Present at Jefferies Global Healthcare Conference

Nov 5, 2025, 9:00 AM EST - 6 months ago

Charles River Laboratories International Earnings Call Transcript: Q3 2025

Nov 5, 2025, 7:34 AM EST - 6 months ago

Charles River raises annual profit forecast on stabilizing biotech demand

Nov 5, 2025, 7:01 AM EST - 6 months ago

Charles River Laboratories Provides Update on Strategic Review

Nov 5, 2025, 7:00 AM EST - 6 months ago

Charles River Laboratories Announces Third-Quarter 2025 Results

Oct 22, 2025, 8:00 AM EDT - 7 months ago

Charles River and the Francis Crick Institute Combine Expertise in Antibody-Drug Conjugate Development

Oct 20, 2025, 8:00 AM EDT - 7 months ago

Charles River and X-Chem Announce Strategic Collaboration to Enhance Hit Identification Capabilities

Oct 15, 2025, 8:00 AM EDT - 7 months ago

Charles River Announces Scientific Advisory Board to Drive Alternative Method Innovation and Adoption

Oct 14, 2025, 8:00 AM EDT - 7 months ago

Charles River Laboratories Schedules Third-Quarter 2025 Earnings Release and Conference Call

Oct 8, 2025, 8:00 AM EDT - 7 months ago

Charles River and Toxys Announce Collaboration to Validate the Use of NAMs for Developmental Toxicity Testing

Sep 16, 2025, 7:05 AM EDT - 8 months ago

Charles River Laboratories Announces Chief Financial Officer Transition

Sep 11, 2025, 8:00 AM EDT - 8 months ago

Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer

Sep 10, 2025, 9:40 AM EDT - 8 months ago

Charles River Laboratories International Transcript: Baird Global Healthcare Conference 2025

Sep 9, 2025, 10:00 AM EDT - 8 months ago

Charles River Laboratories International Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference

Sep 8, 2025, 8:00 AM EDT - 8 months ago

Charles River Laboratories to Present at Baird and Morgan Stanley Conferences

Sep 3, 2025, 8:00 AM EDT - 9 months ago

Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences

Aug 26, 2025, 8:00 AM EDT - 9 months ago

Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing

Aug 6, 2025, 9:00 AM EDT - 10 months ago

Charles River Laboratories International Earnings Call Transcript: Q2 2025

Aug 6, 2025, 7:55 AM EDT - 10 months ago

Charles River raises profit forecast on growing demand for drug development services

Aug 6, 2025, 7:00 AM EDT - 10 months ago

Charles River Laboratories Announces Second-Quarter 2025 Results

Jul 22, 2025, 8:00 AM EDT - 10 months ago

Charles River Joins Elly's Team to Drive Rare Disease Gene Therapy Development

Jul 15, 2025, 8:00 AM EDT - 10 months ago

Charles River Laboratories Schedules Second-Quarter 2025 Earnings Release and Conference Call

Jun 16, 2025, 8:00 AM EDT - 11 months ago

Charles River Announces Endosafe® Cartridge Recycling Program, Strengthening Sustainability Commitment

YouOnlyLiveTwice May. 13 at 2:02 PM

$CRL $TMO These o my one that has growth in excess of 7% is RVTY and the only one w cloud based AI technology

0 · Reply

YouOnlyLiveTwice May. 13 at 1:59 PM

$CRL $TMO These are dead stocks .. They have NO growth ….

1 · Reply

CapitalMonk May. 13 at 3:39 AM

0 · Reply

YouOnlyLiveTwice May. 12 at 7:51 PM

$RVTY $BSX $CRL $TMO

0 · Reply

YouOnlyLiveTwice May. 11 at 3:50 PM

$CRL Nobody wants company w 1% growth when you have tech and industrials growing in double digits

0 · Reply

MarketBeat May. 9 at 11:04 PM

https://marketbeat.com/a/8644554/ $CRL Charles River Laboratories International Q1 Earnings Call Highlights

0 · Reply

StocktwitsEarnings May. 7 at 11:22 AM

0 · Reply

SuperGreenToday Apr. 28 at 6:49 PM

0 · Reply

YouOnlyLiveTwice Apr. 23 at 4:19 PM

$CRL All med device are sells …

0 · Reply

zerodayrounder Apr. 23 at 1:58 PM

$CRL this thing is cooked wow. AI eating its lunch?

0 · Reply

IN0V8 Apr. 15 at 4:04 PM

$CRL Buy Barclays raises target price to $210 from $200

0 · Reply

zerodayrounder Apr. 6 at 9:22 PM

$CRL why did this get smoked today? Trump MFN for drugs not good for these guys?

0 · Reply

koditrump Mar. 16 at 9:45 PM

$CNC $CRL

0 · Reply

koditrump Mar. 16 at 9:43 PM

$CRL $UAMY $TSLA $LYFT

0 · Reply

YouOnlyLiveTwice Mar. 10 at 2:44 PM

$CRL Time to short all medical device companies ….

0 · Reply

Estimize Mar. 9 at 1:06 PM

Wall St is expecting 1.94 EPS for $CRL Q1 [Reporting 05/07 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

smartkarma Feb. 28 at 9:02 PM

$CRL | Charles River Laboratories and China Expansion: Turning Regulatory Localization Into a Growth Advantage! "Charles River Laboratories' fourth-quarter and full-year 2025 financial results reflect a range of dynamics that present both positive and..." - Baptista Research (Baptista Research) Read more: https://www.smartkarma.com/insights/charles-river-laboratories-and-china-expansion-turning-regulatory-localization-into-a-growth-advantage

0 · Reply

Estimize Feb. 23 at 3:00 PM

Wall St is expecting 1.93 EPS for $CRL Q1 [Reporting 05/07 BMO] http://www.estimize.com/intro/crl?chart=historical&metric_name=eps&utm_cont

0 · Reply

SuperGreenToday Feb. 23 at 10:04 AM

$CRL Share Price: $169.00 Contract Selected: Jul 17, 2026 $160 Calls Buy Zone: $18.79 – $23.21 Target Zone: $33.31 – $40.71 Potential Upside: 67% ROI Time to Expiration: 143 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Fletcher_13 Feb. 20 at 6:40 PM

$CRL 545k vol, staying flat until it commits toward 200.46 or rolls over

0 · Reply

RunnerSignals Feb. 20 at 11:31 AM

oversold bounce radar https://stocksrunner.com/news/2026-02-20-oversold-stocks-to-watch-today $CRL $ULS $ETSY $SMWB $PINS starting to wake up off the lows. setups getting interesting

0 · Reply

koditrump Feb. 18 at 7:19 PM

$CRL

0 · Reply

Market Cap	8.11B
Revenue (ttm)	4.02B
Net Income (ttm)	-144.34M
EPS (ttm)	N/A
PE Ratio	17.76
Forward PE	16.15
Profit Margin	-3.59%
Debt to Equity Ratio	0.90

Volume	724,900
Avg Vol	862,128
Day's Range	N/A - N/A
Shares Out	48.17M
Stochastic %K	21%
Beta	1.44
Analysts	Strong Sell
Price Target	$212.86